Skip to main content

Table 1 Comparative bleeding rates for warfarin versus dabigatran, rivaroxaban, apixaban and edoxaban [7]

From: The impact of prothrombin complex concentrates when treating DOAC-associated bleeding: a review

 

RE-LY [5]

ROCKET-AF [6]

ARISTOTLE [136]

ENGAGE-AF TIMI [4]

Dabigatran 150 mg (n = 6076)

Dabigatran 110 mg (n = 6015)

Warfarin (n = 6022)

Rivaroxaban (n = 7111)

Warfarin (n = 7125)

Apixaban (n = 9088)

Warfarin (n = 9052)

Edoxaban 60 mg (n = 7012)

Edoxaban 30 mg (n = 7002)

Warfarin (n = 7012)

Major bleeding rate (%) per year

3.11

2.71

3.36

3.6

3.4

2.13

3.09

2.75

1.61

3.43

Hazard ratio vs warfarin

0.93 (0.81–1.07); p = 0.31

0.80 (0.69–0.93); p = 0.003

/

1.04 (0.90–1.20); p = 0.58

/

0.69 (0.60–0.80); p < 0.001

/

0.80 (0.71–0.91); p < 0.001

0.47 (0.41–0.55); p < 0.001

/